Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814566 | 0.87 | HRH3 (0.55) | HRH3L3MBTL3PDK2JAK2ATR | |
| SCHEMBL2886071 | 0.82 | HRH3 (0.71) | HRH3L3MBTL3PDK2 | |
| SCHEMBL1813947 | 0.82 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL1812862 | 0.82 | HRH3 (0.71) | HRH3KCNH2 | |
| SCHEMBL1812524 | 0.81 | HRH3 (0.55) | HRH3L3MBTL3PDK2JAK2L3MBTL1 | |
| SCHEMBL1811086 | 0.80 | HRH3 (0.72) | HRH3ATRKCNH2 | |
| SCHEMBL1814327 | 0.80 | HRH3 (0.72) | HRH3ATRKCNH2 | |
| SCHEMBL1810394 | 0.80 | HRH3 (0.72) | HRH3ATRKCNH2 | |
| SCHEMBL16151197 | 0.78 | MAPT (0.49) | POLB | |
| SCHEMBL17404603 | 0.78 | SIGMAR1 (0.54) | HRH3L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2074088-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HRH3 3/4885L3MBTL3 2875/4885PDK2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.